MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO		Complete if Known	
FORMATION DISCLOSURE	Application Number	10/677,227	
STATEMENT BY APPLICANT MAR 1 4 2006 Date Submitted:	Filing Date	10/03/2003	
MAR 1 4 2000 W	First Named Inventor	Hiroaki ITO	
<i>D-1</i>	Group Art Unit	1646	
(His as many sheets as necessary)	Examiner Name	Prema MERTZ	
Serence 1 of 1	Attorney Docket Number	053466-0365	

U.S. PATENT DOCUMENTS									
		U.S. Patent	Document		Date of Publication of	Pages, Columns, Lines, Where Relevant			
Examiner Initials*	Examiner Cite No.1 Number Code ² (if known) Name of Patentee or Applicant of Code ² (if known)	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear						
PM	B1	5,888,510		Kishimoto et al.	03/30/1999				

Examiner Cite	Cito	Cite Foreign Patent Document		Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where		
nitials*	No.1	Office	3 Number ⁴	Marie of Faterites of	MM-DD-YYYY	Relevant Passages or Relevant Figures Appear	nt T ⁶	
PM	B2	JP	8-208514		Chugai Pharmaceutical Co. Ltd.; Kishimoto CHUZO	08/13/1996		Abs
	В3	wo	96/00081	A1	Immunex Corporation	01/04/1996		
V	B4	wo	97/38104	А	Applied Research Systems Ars Holding N. V.	10/16/1997		

	_	NON PATENT LITERATURE DOCUMENTS	T
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
PM	B5	IGAKU, Vol. 51, No. 10, 1996, pgs. 111-121, with Partial Translation.	
PM	B6	Jpn. J. Clin. Immun., Vol. 20, No. 2, 1997, pgs. 87-94.	

					_	
Examiner Signature	frema	Ment	Date Considered	10	21	06

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

10/3/03

PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.				Complete if Known
	ubstitute for form 1449	9B/PTO		
	ORMATION DISCL		Application Number	1 0 1 2 2 2
INF	ATEMENT BY APP	HICANT	Filing Date	10/03/2003
			First Named Inventor	Hiroaki ITO et al.
Date	e Submitted: Octobe	er 3, 2003	Group Art Unit	1646
			Examiner Name	Unassigned frem Ment
(use	as many sheets as	. 1 🕿	Attorney Docket Number	053466-0365
Sheet	0	of 2	Attorney Docket Italiaci	

				U.S. PATENT DOCUMENTS		Pages, Columns, Lines,
		U.S. Patent	Document	Name of Patentee or Applicant of	Date of Publication of Cited Document	Where Relevant Passages or Relevant
Examiner cite nitials* No.1		Number	Kind Code ² (if known)	Cited Document	MM-DD-YYYY	Figures Appear
	 					

<u></u>					OREIGN PATENT DOCUMENT	Date of Publication of	Pages, Columns, Lines, Where Relevant	T
Examiner Initials*	Cite No.1	Fo Office ³	oreign Patent De Number ⁴	Kind Code (# known)		Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
PM	A1	wo	96/40966	A	Private Biologicals Corporation	12/19/1996		\perp
	A2	JP	7-324097			11/26/1996		
	A3	JP	8-311098			09/24/1996		
	A4	JP	8-245414			090/9/1997		—
	A5	JP	9-235276			04/16/1996		
	A6	JP	8-99996			09/03/1996		
	A7	JP	8-50829			12/19/1996		
	A8	WO	96/409966		The Board of Regents of	12/05/1996		1
	A9	wo	96/38481	Ì	the University of Oklahoma			+-
	J	<u> </u>			SEIYAKU et al.	12/10/1997		
	A10	WO	0 811 384 99/64069		Ophidian Pharmaceuticals, Inc.	12/16/1999		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		OTHER PRIOR ART - NON PATENT ETTERSTONE	1
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
L		AT 1 Bearing Prevents Inflammatory Bowel Disease In scid Mice	1
PjM	A12	POWRIE et al., "Inhibition of The Responses" Incomplete Vol. 1:53-562 (1994).	
L lat		POWRIE et al., "Inhibition of Th1 Responses Preventing." Vol. 1:553-562, (1994). Reconstituted With CD45Rbhi CD4+ T Cells", Immunity, Vol. 1:553-562, (1994). TAKAGI et al., "Blockage Of Interleukin-6 Receptor Ameliorates Joint Disease In Murine Collagen-Induced TAKAGI et al., "Blockage Of Interleukin-6 Receptor Ameliorates Joint Disease In Murine Collagen-Induced	1
1	A13	TAKAGI et al., "Blockage Of Interieukin-6 Receptor 2404, (1908)	
l i	1	Arthritis", Arthritis Reheumatism, Vol. 41(12):2117-2121, (1998). MITSUYAMA et al., "Soluble Interleukin-6 Receptors In Inflammatory Bowel Disease; Relation To	1
	A14	MITSUYAMA et al., "Soluble Interieukin-o Receptors in Interioris Soluble Interieukin-o Receptors in Interioris Soluble Interieukin-o Receptors in Interioris Soluble	
	1017	Circulating Interleukin-6", Gut, Vol. 36:45-49, (1995). VAN DULLEMEN et al., "Treatment Of Crohn's Disease With Anti-Tumor Necrosis Factor Chimeric VAN DULLEMEN et al., "Grestroenterplany, Vol. 109:129-135, (1995).	
	A15		1
	/	Monoclonal Antibody (CA2), Gastidentelology, Castidentelology, Transfer Transfer of Ulcerative Colitis, Journal of	1
	A16	SASAJIMA et al., *Changes in Serum Cytokine Profile During Treatment of Oldstatt of State of	
	1	Gastroenterology and Hepatology, December 1997, page 7217, 100	

Examiner	R. Must	Date Considered		0.6
Signature	Trema 19447	. Draw line through citation if	not in conformance	e and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English tanguage Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

10/3/03.

PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.	·			Complete if Known
	Substitute for fo	orm 1449B/PTO	<u>C</u>	(3)
7			Application Number	Unassigned 10 6 77, 227
1	INFORMATION	N DISCLOSURE	Filing Date	10/03/2003
I	STATEMENT	BY APPLICANT	First Named Inventor	Hiroaki ITO et al.
	Date Submitted:	: October 3, 2003	Group Art Unit	1646
			Examiner Name	Unassigned Prema Ment
Ì	(use as many shu	eets as necessary)		· · · · · · · · · · · · · · · · · · ·
Sheet	2	of 2	Attorney Docket Number	053400-0505

				U.S. PATENT DOCUMENTS		Pages, Columns, Lines,
		U.S. Patent I		Name of Patentee or Applicant of	Date of Publication of Cited Document	Where Relevant Passages or Relevant
Examiner I Initials*	Cite No.1	Number	Kind Code ² (if known)	Cited Document	MM-DD-YYYY	Figures Appear

				FC	REIGN PATENT DOCUMEN	rs (2)	Pages Columns Lines.	Γ
Cite No.1	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)				Name of Patentee or Applicant of Cited Documents	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ⁶
								
				ļ				↓
				├				+
							<u> </u>	
				No.1 Oct. 3 Number4 Kind C	Cite Foreign Patent Document	Cite Foreign Patent Document Name of Patentee or No. 1	Cite Foreign Patent Documents Applicant of Cited Documents MM-DD-YYYY	Cite Foreign Patent Document Name of Patentee or Applicant of Cited Document MM-DD-YYYY Where Relevant Passages or Relevant Figures Appear

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.						
PM A17		FUNAKOSHI et al., "Spectrum of Cytokine Gene Expression in Intestinal Mucosal Lesions of Cronn's Disease and Ulcerativre Colitis", Digestion, January 1998, pages 73-78, vol. 59, no. 1, Basel, China,						
	A18	1997, pages 271-281, vol. 58, no. 3, Basel, China, Ar-otto: Bowel Disease", Journal of Pediatric	_					
	A19	SEIDMAN et al., "Nutritional Issues in Pediatric Inflammatory Solves Services of Seidman Pediatric Inflammatory Seidman Pedia	-					
_	A20		-					
	A21	382-389. KMIEC, "Cytokines in Inflammatory Bowel Disease," Arch. Immunol. Ther. Exp. (Warsz), Vol. 46, No. 3, 1998, pp. 143-155. HOGEZAND et al., "Selective Immunomodulation in Patients With Inflammatory Bowel Disease-Future HogeZAND et al., "Selective Immunomodulation in Patients With Inflammatory Bowel Disease-Future	+					
V	A22	HOGEZAND et al., "Selective immunomodulation in automotive and the selective and the						

	10		Date	fo	24	06
Examiner	1	Meny	Considered	1.0		
Signature	Freme	1 0.7.	 Draw line through citation if	not in con	orman	ice and not

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if a possible of the patent of the p

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.